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Type 1 conventional DCs (cDC1) excel in the cross-priming of CD8+ T cells, which is
crucial for orchestrating efficient immune responses against viruses or tumors. However,
our understanding of their physiological functions and molecular regulation has been
limited by the lack of proper mutant mouse models allowing their conditional genetic
targeting. Because the Xcr1 and A530099j19rik (Karma/Gpr141b) genes belong to the
core transcriptomic fingerprint of mouse cDC1, we used them to engineer two novel
Cre-driver lines, the Xcr1Cre and KarmaCre mice, by knocking in an IRES-Cre expression
cassette into their 3
′
-UTR. We used genetic tracing to characterize the specificity and
efficiency of these new models in several lymphoid and non-lymphoid tissues, and
compared them to the Clec9aCre mouse model, which targets the immediate precursors
of cDCs. Amongst the three Cre-driver mouse models examined, the Xcr1Cre model
was the most efficient and specific for the fate mapping of all cDC1, regardless of the
tissues examined. The KarmaCre model was rather specific for cDC1 when compared
with the Clec9aCre mouse, but less efficient than the Xcr1Cre model. Unexpectedly, the
Xcr1Cre model targeted a small fraction of CD4+ T cells, and the KarmaCre model a
significant proportion of mast cells in the skin. Importantly, the targeting specificity of
these two mouse models was not changed upon inflammation. A high frequency of
germline recombination was observed solely in the Xcr1Cre mouse model when both the
Cre and the floxed alleles were brought by the same gamete irrespective of its gender.
Xcr1, Karma, and Clec9a being differentially expressed within the cDC1 population,
the three CRE-driver lines examined showed distinct recombination patterns in cDC1
phenotypic subsets. This advances our understanding of cDC1 subset heterogeneity
and the differentiation trajectory of these cells. Therefore, to the best of our knowledge,
upon informed use, the Xcr1Cre and KarmaCre mouse models represent the best tools
currently reported to specifically and faithfully target cDC1 in vivo, both at steady state
and upon inflammation. Future use of these mutant mouse models will undoubtedly
boost our understanding of the biology of cDC1.
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INTRODUCTION
Dendritic cells (DCs) constitute a heterogeneous population of
antigen presenting cells (APCs) which are instrumental for the
orchestration of innate and adaptive immune responses. In mice
and in humans, three distinct types of DCs differing in their
phenotype, localization and functions populate all lymphoid
and most non-lymphoid tissues at steady state. Plasmacytoid
DCs (pDCs) are the major source of type I interferon (IFN)
upon many viral infections. Conventional DCs (cDCs) consist
of two populations, coined as type 1 and type 2 cDCs and
which excel in the cross-priming of CD8+ T cells or in the
promotion of CD4+ T cell and humoral immunity, respectively.
The functions of cDCs and their molecular regulation have
been studied in vivo by using a wealth of mouse models that
enable their depletion or genetic manipulation, namely Cd11c
(Itgax)hDTR (1) or Cd11c (Itgax)Cre (2, 3) and more recently the
Zbtb46hDTR (4) or Zbtb46Cre (5). However, interpretation of the
results obtained using those mice can be difficult due to the
expression of Cd11c by many other cell types than cDCs and of
Zbtb46 by committed erythroid progenitors and endothelial cell
populations (6). Moreover, these mutant mouse models are not
suited to study the respective functions of each of the two cDC
types. This goal requires the use of refined mutant mouse models
enabling specific targeting of either cDC1 or cDC2.
Constitutive (Batf3-KO mice) or conditional (ItgaxCre; Irf8fl/fl
mice) genetic inactivation of transcription factors required for
the differentiation of cDC1 allowed to study their specific
functions in vivo (7, 8). However, interpretation of the results
obtained with these models can be difficult because they are not
targeting solely cDC1 (7, 9–11). Moreover, cDC1 are replenished
in Batf3-KO mice under inflammatory conditions, due to
expression of other Batf transcription factors that compensate for
Batf3 loss (12). Finally, these models do not allow the editing of
cDC1 genome, which would be a powerful method to decipher
the molecular regulation of their functions. Hence, novel mutant
mouse models are needed to reach this goal.
In all tissues with the exception of the intestine, cDC1 can be
defined as CD24+ SIRPα/CD172a− cDCs (13–15). In addition,
lymphoid-tissue resident cDC1 express CD8α, whereas the cDC1
residing in the parenchyma of non-lymphoid tissues and their
counterparts that have migrated in secondary lymphoid organs
express CD103. CLEC9A, a C type lectin receptor that allows
efficient cross-presentation by cDC1 of dying cell-associated
antigens (16) has been identified as a good candidate to generate
mice enabling selective targeting of cDC1 in vivo due to its
selective expression in these cells and to a lesser extent in pDCs
(17–20). However, a thorough analysis of mice expressing a Cre
recombinase under the Clec9a promoter showed that Cre-driven
recombination occurred not only in cDC1 and to some extent in
pDCs, but also in cDC2, leading to the discovery that Clec9a is
expressed in a progenitor cell common to both cDC types (21).
Hence, the Clec9aCre mouse is not suitable for specific targeting
of cDC1.
A major breakthrough in the field of cDC1 was the
identification of XCR1 as a universal marker of all cDC1
regardless of their tissues of residency, and present in all the
warm-blooded vertebrate species studied to date (22–27). Xcr1
encodes the chemokine receptor XCR1, which ligand XCL1 is
strongly upregulated in natural killer (NK) cells, CD8+ T cells
and memory T cells upon activation in mice (24, 26, 28–31).
Recently, a mouse model based on the expression of the Cre
recombinase under the control of the Xcr1 promoter has been
generated to specifically manipulate gene expression in cDC1.
This mutant mouse model was engineered by replacing the single
coding exon of Xcr1 by the Cre gene (32). This strategy assumes
that the Xcr1 gene is haplosufficient. However, this hypothesis
has to be tested considering that XCR1 promotes the cross-
talk between cDC1 and NK cells or CD8+ T lymphocytes, by
facilitating their reciprocal recruitment and/or activation (24, 26,
29). Regardless of its potential limitation, this Xcr1tm4(cre)Ksho
mouse model has been useful to decipher the role of cDC1
in intraepithelial T cell homeostasis in the intestine (32).
However, to the best of our knowledge, it has not been used
yet for conditional gene targeting of the cDC1 lineage. Besides
Xcr1, the A530099j19rik gene (named Karma hereafter) has
also been identified as selectively expressed in cDC1 by bulk
transcriptomic analysis on immune cell subsets and organs (10,
33). The Karma gene encodes a protein with 7 transmembrane
domains, likely corresponding to a G protein-coupled receptor,
leading to its recent denomination as Gpr141b by the Mouse
Genome Informatics. Recently, we generated the Karma knock-
in reporter/deleter mouse model, which expresses in the Karma
locus a construct encoding both the fluorescent tandem dimer
Tomato (tdTomato) and the human diphtheria toxin receptor
(hDTR), allowing specific tracking and conditional depletion of
cDC1 in vivo. Results obtained with this reporter mouse validated
the Karma locus as highly reliable to functionally target cDC1 in
vivo (33).
To match the unmet need of a mouse model allowing specific
and efficient in vivo genetic manipulation of cDC1, we generated
two novel Cre-driver lines, the Xcr1Cre and KarmaCre mice, by
knocking in an IRES-Cre expression cassette in the 3′-UTR
of the Xcr1 or Karma locus, respectively. In this study, we
used genetic tracing to characterize the specificity and efficiency
of the Cre-mediated recombination in these new models at
steady state and upon infection, and compared them with the
Clec9aCre model. This study also advanced our understanding
of the phenotypic heterogeneity of cDC1 with regard to their
differentiation trajectory.
MATERIALS AND METHODS
Generation of cDC1 Targeting Cre
Constructs and Mice
Xcr1Cre (B6-Xcr1tm1Ciphe) and KarmaCre (B6-Gpr141btm2Ciphe)
mice were made according to a standard gene targeting approach
in C57BL/6N-derived ES cells. They were constructed by
inserting, through ET homologous recombination, a cassette
containing the internal ribosome entry site (IRES) followed by a
gene encoding the codon-improved version of Cre recombinase
(34), into the 3
′
-UTR of the Xcr1 or A530099j19rik/Gpr141b
genes, 34 and 98 bp after the stop codon, respectively. These
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mice were outcrossed for three generations with wild type (Wt)
C57BL/6J mice purchased from Charles River Laboratories.
All experiments were performed with sex-matched littermate
mice at 6–12 weeks of age. Clec9aCre (Clec9atm2.1(icre)Crs) (21)
knock-in mice [kindly provided by Caetano Reis e Sousa
(The Francis Crick Institute, UK)], Karma-tdTomato-hDTR
(Gp141btm1Ciphe) (33) were maintained on the C57BL/6J
background. Rosa26lox−stop−lox−tdRFP (Gt(ROSA)26Sortm1Hjf )
mice in which expression of the tandem dimer Red Fluorescent
Protein (tdRFP) is driven through the deletion of a “lox–
stop–lox” sequence (35) were purchased from the Jackson
Laboratory and maintained on the C57BL/6J background.
Rosa26lox−stop−lox−DTA (Gt(ROSA)26Sortm1(DTA)Lky) mice in
which expression of active domain of the diphtheria toxin (DTA)
is driven through the deletion of a “lox–stop–lox” sequence
(36) were obtained from Prs. David Voehringer and Richard
M. Locksley, and maintained on the C57BL/6J background.
Mice were bred and maintained in our specific pathogen—free
animal facility. This study was carried out in accordance with
institutional guidelines and with protocols approved by the
Comité National de Réflexion Ethique sur l’Expérimentation
Animale #14.
Preparation of Cell Suspension From Blood
and Tissues, and Analysis by Flow
Cytometry
Splenocytes were prepared by infusing spleens with an enzymatic
cocktail made of Collagenase D (1 mg/ml) and DNase I
(70µg/ml, both Roche) in plain RPMI 1640, and further
incubation for 25min at 37◦C. Ice cold EDTA (2mM) was
added for additional 5min. Cells were filtered through a 70-µm
nylon sieve, and exposed to 0.155M NH4Cl, 10mM KHCO3,
0.127M EDTA to lyse red blood cells. Liver and lungs were
minced in an enzymatic cocktail (1 mg/ml of Collagenase D and
70µg/ml of DNase I), incubated for 25min at 37◦C. Ice-cold
EDTA (2mM) was added for additional 5min, then digested
tissues were filtered through a 70µm nylon sieve (BD Falcon).
Low-density cells were further enriched by centrifugation over
a 1.069 g/ml density gradient (OptiPrep, Axis-Shield), washed
and resuspended in PBS, EDTA 2mM, 2% BSA, and red blood
cells were lysed as detailed above. Cutaneous LNs (inguinal and
axillar LNs) were cut into small pieces and digested for 25min
at 37◦C with a mixture of type II collagenase (Worthington
Biochemical) and DNase I (Sigma-Aldrich) in plain RPMI 1640.
The resulting cell suspension was treated with 5mM EDTA and
filtered through a 70µm nylon sieve (BD Falcon). For the skin,
ears were split into a ventral and dorsal parts and incubated
for 105min at 37◦C in RPMI containing 0.25 mg/ml Liberase
TL (Roche Diagnostic Corp.) and 0.5 mg/ml DNase I (Sigma
Aldrich). Digested tissue was homogenized using Medicons and
Medimachine (Becton Dickinson) to obtain homogenous cell
suspensions. For skin mast cells, we used a protocol recently
described (37). To test the germline recombination in blood
cells, peripheral bloodmononuclear cells (PBMCs) were enriched
by centrifugation over a 1.077 g/ml density gradient (Ficoll-
Paque Plus, GE Healthcare), washed and resuspended in PBS,
EDTA 2mM, 2% BSA before staining. Staining of cells for flow
cytometry started with a pre-incubation with 2.4G2 mAb to
block unspecific binding to Fc-receptors. Staining with mAb
(Supplementay Table S1) was then performed in PBS, 2% BSA,
2mM EDTA for 25min on ice. For exclusion of dead cells
4′,6-diamidino-2-phenylindole (DAPI, Thermo Fisher Scientific)
was added 5min before acquisition. Data were acquired on a
LSRFortessa X-20 flow cytometer (BD Biosciences), and analyzed
using FlowJo (Tree Star, Inc.).
Bone Marrow-Derived DC Differentiation
FLT3-L-BMDCs were generated as described (38) with some
modifications. BM cell suspensions were prepared and red blood
cells were lysed as detailed in the previous section. After washing
in complete RPMI 1640 medium, cells were cultured at 3 × 106
cells/ml in 24 well plates, with 10% FBS, RPMI 1640 medium
containing murine FLT3-L (in house supernatant from B16-Flt3l
cells, used at 1/20 final) at 37◦C in 5% CO2. Four days after, half
of the culture medium was replaced by fresh FLT3-L. Cells were
harvested at indicated times for flow cytometry analysis after
staining for CD11c, SiglecH, CD24, SIRPα, XCR1, and CD11b
(Supplementay Table S1).
Microarray Data Generation and Analysis
DCs were generated in vitro from mouse BM FLT3-L cultures
and sorting by flow cytometry to over 98% purity, as live, singlet,
CD11c+ cells that were SiglecH+ for eq-pDCs, SIRPα−CD24high
for eq-cDC1 and SIRPα+CD24−/low for eq-cDC2. Total RNA
(50 ng) was used as starting material for each sample to
synthesize biotinylated probes, using the NuGen protocol as
described previously (39). Affymetrix Mouse Gene 1.0 ST raw.
CEL files were analyzed in the R statistical environment (version
3.4.1). Data were RMA normalized using the oligo package
and processed as described previously (40). Heatmaps of Log2-
normalized expression values of selected genes were performed
using the Morpheus website from the Broad Institute (https://
software.broadinstitute.org/morpheus/). Hierarchical clusterings
were performed using the One-Pearson correlation as a metric
and the average linkage as a clustering method for samples
and genes, except for Figure 5B where the complete linkage
method was used for the genes. The microarray data have been
deposited in the GEO database under the series accession number
GSE121859.
Mouse Cytomegalovirus Infection
Animals were infected intraperitoneally with 2 × 105 PFU
of salivary gland-extracted MCMV Smith strain (3rd in vivo
passage). Forty-Eight hours later, spleen and liver were harvested
and prepared for flow cytometry analysis as described above.
Analysis of Germline Recombination
Four females and 2 males of each Xcr1Cre/wt ; Rosa26tdRFP/wt
and KarmaCre/wt ; Rosa26tdRFP/wt genotype were backcrossed to
C57BL/6J mice. Their progeny was genotyped and bled to analyse
tdRFP expression in circulating T and B cells as a sign of germline
recombination.
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RESULTS
Generation of New cDC1-Targeting
Cre-Driver Lines
By comparative gene expression profiling, we and other have
previously identified Xcr1 and a530099j19rik (Gpr141b/Karma)
genes as specifically expressed by mouse cDC1 in different
tissues throughout the body (10, 22–26, 31, 33). We used such
unique gene expression profile to genetically target cDC1 in vivo
by generating Xcr1Cre (Figure 1A) and KarmaCre (Figure 1B)
knock-in mouse models. The insertion of an IRES-Cre cassette
after the STOP codon of Xcr1 and Karma genes allows the
translation of two separate proteins resulting in the expression
of the Cre recombinase. Expression of endogenous XCR1
was not significantly altered in the Xcr1Cre mouse model
(Supplementary Figure S1A, top).
The XCR1Cre Mouse Model Allows
Selective and Efficient Recombination of
loxP Sequences in Migratory and Resident
cDC1 in All Tissues Examined
To determine the specificity of the Cre-induced recombination
in Xcr1Cre (Figure 1A) and KarmaCre (Figure 1B) mice, we bred
them with the Cre-reporter line Rosa26lox−stop−lox−tdRFP
(named hereafter Rosa26tdRFP) (35), and analyzed the
tdRFP expression pattern in immune cells of lymphoid
organs [spleen and cutaneous lymph-nodes (CLNs)]
(Supplementary Figures S1A,B) and non-lymphoid tissues
(lungs, liver, and skin) (Supplementary Figures S1C–E).
To define DC cell populations, we applied gating strategies
adapted from (41). As a control Cre-driver line, we used
the Clec9aCre mice (21) bred to Rosa26tdRFP. Regardless of
the tissues examined, we found that all three mouse models
achieved effective targeting of the cDC1-lineage, with Xcr1Cre,
and Clec9aCre being the most efficient (Figure 2). In contrary
to Clec9aCre, the Xcr1Cre and KarmaCre mouse models did
not show any significant Cre activity, neither in pDCs nor
in macrophages (Figure 2). However, Cre recombination
(tdRFP signal) was detected in a fraction of other cell types. In
Xcr1Cre/wt ; Rosa26tdRFP/wt mice, a minute proportion (<1%)
of CD4+ T cells expressed tdRFP in the spleen, CLNs, lung
and liver, which increased to a much higher fraction of CD4+
T cells in the skin (8.4 ± 6.4%). The CD4+ T cells harboring
Xcr1-driven Cre recombination lacked detectable level of XCR1
(Supplementary Figure S1E, bottom). Hence, they likely derived
from progenitors cells that transiently expressed Xcr1. In the
skin, lungs and CLNs of KarmaCre/wt ; Rosa26tdRFP/wt mice, a
fraction of cDC2 had undergone recombination, although to a
lesser extent than in Clec9aCre/wt ; Rosa26tdRFP/wt mice where
cDC2 were targeted in all tissues (Figure 2). Surprisingly, in the
skin of KarmaCre/wt ; Rosa26tdRFP/wt mice, a large proportion of
mast cells (61.1± 12.8%) also expressed the tdRFP (Figure 2).
To further assess cDC1-targeting specificity in the three
Cre-driver mouse strains, we analyzed the proportion of
different immune cell types within the tdRFP+ cells (Figure 3,
Supplementary Figure S2). As expected on the basis of previous
report (21), other cells than cDC1, in particular cDC2 and
to some extent pDCs, represented the major fraction of the
cells targeted in Clec9aCre mice (Figure 3). In contrast, in all
examined organs, except for the CLNs, cDC1 represented the
major fraction of the cells targeted in Xcr1Cre mice, CD4+ T
cells constituting the second most frequent cell types expressing
tdRFP in these organs, and the most frequent in the CLNs.
This reflects the higher numbers of CD4+ T cells as compared
to cDC1s in all these organs. Finally, cDC1 represented the
major fraction of targeted cells in KarmaCre mice in all examined
organs, except for the skin where 64.4 ± 5.8% of the tdRFP+
cells were mast cells (Figure 3). We assessed the expression
pattern of the Karma gene in mast cells and compared it to
a variety of other immune cell types, using the database from
the Immgen consortium. These results revealed that mast cells
express similar levels of the Karma gene as cDC1 in all organs
examined, trachea, tongue, esophagus, skin, and peritoneal cavity
(Supplementary Figure S3), consistent with the efficient genetic
tracing of mast cells in the skin of KarmaCre mice. Altogether,
these results show that our novel Xcr1Cre and KarmaCre mouse
models constitute the most reliable Cre-driver lines reported to
date for selective and efficient in vivo targeting of cDC1, with the
Xcr1Cre model performing the best. However, it should be noted
that a small fraction of CD4+ T cells is targeted in Xcr1Cre mice
and that mast cells are largely targeted in KarmaCre animals.
FIGURE 1 | Schematic representations of Xcr1Cre and KarmaCre genetic constructions. A cassette containing an IRES sequence upstream of a gene encoding a
codon-improved CRE recombinase was inserted by homologous ET recombination downstream of the stop codon of Xcr1 exon 2 (A) and of
a530099j19rik/Karma/Gpr141b exon 2 (B) genes, to produce Xcr1Cre and KarmaCre mouse mutants, respectively, on a C57BL/6J background.
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FIGURE 2 | Xcr1Cre and KarmaCre mouse models target with high specificity cDC1 in lymphoid and non-lymphoid tissues. Flow cytometry analysis of the tdRFP
expression by different immune cell populations (as defined in Supplementary Figure S1), from spleen, CLNs, lungs, liver, and skin of Xcr1Cre/wt; Rosa26tdRFP/wt,
KarmaCre/wt; Rosa26tdRFP/wt and Clec9aCre/wt; Rosa26tdRFP/wt mice. Gating strategies are detailed in Supplementary Figure S1. Data show one dot per
individual value, mean +/– SEM per group, and are from two pooled experiments with at least two mice per group.
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FIGURE 3 | Proportion of cell types within tdRFP+ cells in the skin, spleen, and CLNs of each genotype. The back gating strategy used to define the relative
proportions of cell types among tdRFP+ cells was performed by using the antibody staining detailed in the upper side of Supplementary Figure S1. Exceptions
were made as follow for Xcr1Cre/wt; Rosa26tdRFP/wt mice: to define further the tdRFP+ cells that fell within the Lin+ (CD19/CD3ε/NKp46/Ly6G) gate, the antibody
staining detailed in the bottom side of Supplementary Figure S1 was used. The proportion of CD4+ T lymphocytes within tdRFP+ cells when using the latter
(“lymphoid”) antibody panel was matching the proportion of Lin+ cells within tdRFP+ cells when using the former antibody (“myeloid”) panel. For KarmaCre/wt;
Rosa26tdRFP/wt mice, mast cells were defined as Lin− CD11b− CD11c− XCR1− MHC-II− CD64− F4/80− FcεRIα+ CD117+. Others: sum of all the other cell
subsets not detailed in the pie charts. Neg. for all, negative for all: cells that did not stain positive for the markers used in the upper antibody panel. Data are shown for
one experiment representative of three with three mice per group.
The Use of Different cDC1-Specific
Promoters for Driving Cre Expression
Reveals Heterogeneity in the cDC1
Population Defined as CD24+ SIRPα−
cDCs
To try understanding the lower efficiency of the KarmaCre model
for cDC1 targeting, as compared to the Xcr1Cre or Clec9aCre
mice, we examined the expression pattern of the tdRFP reporter
within the splenic cDC1 defined as CD24+SIRPα− cDCs (gated
in the CD45+Lin−SiglecH−MerTK−CD64−CD11c+MHC-
II+CD26+ cells) (13). CD24+SIRPα− cDC1 can be split into
4 subsets according to their heterogeneous expression of
CD8α and XCR1 (Figure 4). XCR1 expression was reported to
correlate with a better crosspresentation by cDC1 (23, 42). The
CD8α+XCR1+ cDC1 subset was reported to be phenotypically
and functionally homogenous (23, 42), and likely corresponds
to full-fledged differentiated cDC1 endowed with a high
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FIGURE 4 | Tracing of Xcr1 and Karma expression in the cDC1 population in spleen. Flow cytometry analysis of the tdRFP expression in the 4 CD24+ cDC1 subsets
defined as CD8α+XCR1−, CD8α+XCR1+, CD8α−XCR1+, and CD8α−XCR1−, in the spleen of Xcr1Cre/wt; Rosa26tdRFP/wt, KarmaCre/wt; Rosa26tdRFP/wt, and
Clec9aCre/wt; Rosa26tdRFP/wt mice. Data show one dot per individual value, mean +/- SEM per group, and are from two pooled experiments with at least two mice
per group. Statistical analyses were performed using nonparametric Mann-Whitney tests in all experiments (**, p < 0.01; n.s, non-significant).
crosspresentation activity (43). However, the three other cDC1
subsets, CD8α+XCR1−, CD8α−XCR1+, and CD8α−XCR1−,
have not been extensively characterized. The CD8α−XCR1− cells
may encompass pre-cDC1 (13, 44). The CD8α−XCR1+ cells
likely correspond to pre-terminally differentiated cDC1. The
CD8α+XCR1− cells could correspond to the small fraction of
homeostatically matured splenic cDC1 that have downregulated
XCR1 expression, similarly to what occurs at steady state in
the skin, the intestine or the thymus (25, 32, 39). It could
also be possible that XCR1− cells encompass other cell types
contaminating the SIRPα−CD24+ cDC1 gate. However,
the exclusion of CD3ε+ and SiglecH+ cells in our gating
strategy ensured that the CD8α+XCR1− cDC1 subset was not
contaminated by CD8+ T cells nor CD8α+ pDCs (45–47).
Consistent with the early expression of Clec9a starting at the
pre-DC stage (21), Clec9aCre model targeted efficiently all 4
subsets, regardless of XCR1 and CD8α acquisition, with more
than 85% of the cells in each subset expressing tdRFP (Figure 4).
Although the Xcr1Cre model was more efficient in targeting
XCR1+ cDC1 as initially expected, a significant Cre activity was
also detected both in XCR1−CD8α− and XCR1−CD8α+ cDC1
subsets, with 37% and 53% of tdRFP expression, respectively
(Figure 4). This indicated that a significant proportion of these
cells from these two subsets derived from XCR1-expressing
precursors, consistent with the hypothesis that they respectively
encompass pre-cDC1 and terminally matured cDC1. The
KarmaCre model was effective in targeting the XCR1+CD8α+
cDC1 subset, contrasting with no recombination detected in the
XCR1−CD8α− subset and with only a weak Cre activity in the
XCR1+CD8α− subset (Figure 4). The fraction of XCR1−CD8α+
cDC1 targeted in KarmaCre mice (22.8 ± 6.1%) was lower than
that of XCR1+CD8α+ cDC1 (69.0 ± 2.1%). This suggest that
most of XCR1−CD8α+ cDC1 do not derive from XCR1+CD8α+
cDC1 contrary to our expectation that the majority of the
former cells correspond to an advanced maturation state
of the latter ones. Altogether, the combined use of our fate
mapping mouse models suggests consecutive expression of
the corresponding genes along the differentiation of the cDC1
lineage in the spleen, with Clec9a expressed from the common
cDC progenitor stage, Xcr1 likely starting at the pre-cDC1
stage and Karma turned on only at a later stage similarly to
CD8α.
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Comparison of the Three Fate Mapping
Mouse Strains Advances Our
Understanding of the Differentiation
Trajectory of cDC1
We further investigated to which extent our fate mapping
mutant mouse models could help refining the differentiation
trajectory of cDC1, using as a simple model bone marrow (BM)
cells cultured with Fms-like tyrosine kinase 3 ligand (FLT3-
L) (38). This model allows in vitro generation of three subsets
of DCs, which are phenotypically and functionally equivalent
to in vivo cDC1 (eq-cDC1), cDC2 (eq-cDC2) and pDCs (eq-
pDCs) (38, 48–50). To refine the differentiation trajectory of
cDC1, we followed the acquisition of the tdRFP signal over time
in FLT3-L-differentiated DCs generated from BM of our fate
mapping mutant mice (Supplementary Figure S4, Figure 5A).
Xcr1Cre and Clec9aCre models allowed efficient recombination
in eq-cDC1 (56 vs. 90%) (Figure 5A). Interestingly, KarmaCre
did not present any recombinase activity in any of the DC
populations (Figure 5A). Consistently, whereas gene expression
profiling of the eq-DC subsets generated in standard BM FLT3-
L cultures confirmed their close homology to their in vivo
counterparts isolated from the spleen (Figure 5B), it also showed
that eq-cDC1 lacked expression of the Karma, Cd8a and Ly75
(Cd205) genes (Figure 5B, black arrows). This was confirmed
using our previously published Karma reporter mouse model
knocked-in for tdTomato in the 3′UTR of the Karma gene
(33) (Supplementary Figure S5A). However, these eq-cDC1
acquired Karma and CD8α expression upon in vivo transfer
(Supplementary Figures S5B,C). Karma was also expressed in
eq-cDC1 differentiated from BM cells cultured with FLT3-L on
feeder cells expressing the Notch ligand Delta-like 1 (Figure 5C,
black arrows), similarly to what has been recently reported
for CD8α and CD205 expression (43). Altogether, these results
demonstrate a sequential expression of Clec9a, Xcr1 and Karma
during cDC1 ontogeny, with Clec9a being induced early starting
at the common cDC progenitor stage (21), then followed by
Xcr1 which induction might be initiated already at the pre-cDC1
stage. Likewise to CD8α, Karma is acquired at a more advanced
differentiation stage that is not reached under classical conditions
of DC differentiation from BM in FLT3-L in vitro cultures but
can be promoted by Notch signaling. This work thus significantly
extends two recent studies showing that cDC1 derived in
vitro from mouse or human hematopoietic precursors with a
combination of cytokines and growth factors need additional
signals to reach a terminal state of differentiation including
acquisition of CD8α expression for mouse cDC1 (43, 51).
The Cre Expression Under Xcr1 or Karma
Promoters Remains cDC1-Specific Upon
Infection-Induced Inflammation
The expression of many membrane proteins or transcription
factors changes upon inflammation (12, 52). An important
incentive for generating Xcr1Cre and KarmaCre models, was that
the expression of theXcr1 andKarma genes was specific for cDC1
both at steady state and under inflammatory conditions (53).
To confirm this observation based on transcriptomic studies,
we examined cDC1-targeting specificity of the KarmaCre and
Xcr1Cre mouse models in an inflammatory context, namely
systemic mouse cytomegalovirus (MCMV) infection, using the
Rosa26tdRFP reporter as a read out. We adapted a gating strategy
adapted from (52) to identify inflammatory DCs (InflDCs) in
spleen and liver (Supplementary Figure S6). Although we could
observe the appearance of InflDCs upon MCMV infection,
tdRFP expression remained unchanged in infected animals as
compared to control mice, being still essentially confined to
the cDC1 population, both in Xcr1Cre/wt ; Rosa26tdRFP/wt and
KarmaCre/wt ; Rosa26tdRFP/wt mice (Supplementary Figure 6).
This demonstrated that both cDC1-targeting models are stable
and allow excision of a floxed genomic sequence efficiently and
largely selectively in cDC1 at steady state and upon inflammation.
Germline Recombination of loxP
Sequences Is Frequent in the Offspring of
Xcr1Cre but Not KarmaCre Mice
Recombination of loxP-flanked genomic sequences in germ cells
have been described in many Cre mouse models (54–56). To test
whether germline recombination occurs in our cDC1-targeting
Cre-driver lines, we backcrossed Xcr1Cre/wt ; Rosa26tdRFP/wt
and KarmaCre/wt ; Rosa26tdRFP/wt mice to C57BL/6J mice, and
analyzed their offspring for ubiquitous tdRFP expression, using
blood T and B cells as a readout (Figure 7A). Total or partial
germline recombination of the Rosa26tdRFP locus occurred in
95% of the offspring who had inherited one loxP-flanked
allele from Xcr1Cre/wt ; Rosa26tdRFP/wt male mice (Figure 7B).
Germline recombination occurred with the same frequency
irrespective of the segregation of the paternal Cre and loxP-
flanked alleles in the offspring, demonstrating that this process
occurred during meiosis rather than in the embryo. No germline
recombination was observed when both alleles were from
maternal germ cells (Figure 7B). In ongoing crosses using the
Xcr1Cre mouse model with different loxP-flanked mouse strains,
we could also observe germline recombination in the progeny
even when the floxed alleles were brought together with the
Xcr1Cre allele by the maternal gamete (data not shown). This
indicates that, contrary to what the results of the Rosa26tdRFP/wt
backcross appears to suggest, off-target activity of the Cre
recombinase in germline is not a gender effect. Additionally,
the incidence of germline recombination depended on the loxP-
flanked allele (data not shown). No occurrence of germline
recombination was detected so far for the KarmaCre model
(Figure 7B). Therefore, the KarmaCre model might be more
appropriate than the Xcr1Cre model to obtain rapidly mice
in which cDC1 are inactivated for candidate genes, through
conventional breeding strategies. Germline recombination in
the offspring should however always be assessed for any novel
loxP-flanked allele.
DISCUSSION
Xcr1 and A530099j19rik (Karma/Gpr141b) genes code for the
chemokine receptor XCR1 and for the putative G protein-
coupled receptor Gpr141b, respectively, and are among the core
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FIGURE 5 | Sequential regulation of Clec9a, Xcr1 and Karma expression during cDC1 differentiation. (A) Kinetic analysis of the tdRFP expression in DCs differentiated
in vitro from Xcr1Cre/wt; Rosa26tdRFP/wt, KarmaCre/wt; Rosa26tdRFP/wt and Clec9aCre/wt; Rosa26tdRFP/wt BM cells cultured with FLT3-L. Eq-cDC2 were gated as
(Continued)
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FIGURE 5 | CD11c+MHC-II+CD24−SIRPα+ cells, and eq-cDC1 as CD11c+ MHC-II+CD24+SIRPα− cells (Supplementay Figure S4). Data are shown for one
experiment representative of two, with three mice per group. (B,C) Heatmaps display the expression profiles of archetypical genes previously shown to be selectively
expressed in cDC1, cDC2, or pDC. (B) Gene expression across DC types either isolated from murine spleens (sp-pDC, sp-cDC1, and sp-cDC2), or derived in vitro in
standard FLT3-L BM cultures (eq-pDC-FL, eq-cDC1-FL, and eq-cDC2-FL), as assessed with microarrays. (C) Gene expression patterns across cDC types derived in
vitro from FLT3-L BM cultures under standard conditions (-FL) or on DL1-expression OP9 feeder cells (-FL-DL1), as assessed from public RNA-seq data (GEO
accession number GSE110577).
FIGURE 6 | Xcr1 and Karma expressions remain confined to cDC1 upon virus-induced inflammatory responses. Flow cytometry analysis of the tdRFP expression by
different immune cell populations as in Figure 2A, from spleen, CLNs, and liver of Xcr1Cre/wt; Rosa26tdRFP/wt, and KarmaCre/wt; Rosa26tdRFP/wt mice 2 days after
MCMV infection. Cell population gating strategy detailed in Supplementay Figure S3. Data show one dot per individual value, mean +/- SEM per group, and are
from two pooled experiments with at least three individuals per group of infected mice. Statistical analyses were performed using nonparametric Mann-Whitney tests
when possible, and the difference between non infected and infected was non-significant in each cell population. NI, non-infected; InflDCs, inflammatory DCs.
gene signature specifically identifying mouse cDC1 throughout
the organism (10, 22–25, 33). We have inserted an IRES-Cre
cassette into the 3
′
UTR of the Xcr1 and Karma coding exon to
generate Xcr1Cre and KarmaCre mouse models, respectively. In
this study, we have characterized the efficiency and specificity
of Cre-mediated recombination in these novel mouse models
at steady state and upon viral infection, comparing them to
the Clec9aCre model. To the best of our knowledge, this study
demonstrated that our novel Xcr1Cre and KarmaCre mouse
models are the most trustful and robust for the genetic tracking
and manipulation of cDC1 in vivo.
Amongst the three Cre-driver mouse models examined,
Xcr1Cre model is the most efficient and specific for fate
mapping all cDC1 regardless of the tissues examined. The
KarmaCre model is rather specific for cDC1 when compared
with Clec9aCre mouse, but much less efficient than the
Xcr1Cre model. Unexpectedly, a fraction of CD4+ T cells
is labeled with tdRFP in the Xcr1Cre;Rosa26tdRFP/wt mouse
(Figure 2) without expressing any detectable XCR1 at their cell
surface (Supplementary Figure S1E). Further analysis need to be
conducted to determine whether XCR1 was transiently turned on
in the distant progenitors of these cells or on the contrary during
their terminal differentiation. Interestingly, the proportion of
Xcr1cre fate-mapped CD4+ T cells was much higher in the skin
than in the other organs examined, suggesting that these cells
may be polarized toward specific functions and/or develop under
instructive signals encountered preferentially in barrier organs.
Further studies will be needed to test these hypotheses. In the
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FIGURE 7 | The Cre expression under Xcr1 but not Karma promoter efficiently recombines Lox-sequences in germ cells. (A) Representative flow cytometry analysis of
tdRFP expression in CD19− TCRβ−, B and T cells in blood of mice with no germline recombination, partial recombination, and germline recombination. One sample
representative of each is shown. (B) Analysis of germline recombination in offspring from backcrosses of Xcr1Cre/wt; Rosa26tdRFP/wt and KarmaCre/wt;
Rosa26tdRFP/wt mice of both sexes with wild-type (WT; C57BL/6J) mice. Germline recombination shown here occurred when both Cre and floxed alleles were of
paternal origin. However, with other type of flox constructs, we regularly observed occurrences of germline recombination when both alleles were brought together,
either by the father or by the mother.
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skin of the KarmaCre; Rosa26tdRFP/wt mouse model, the vast
majority of the tdRFP+ cells were of mast cell origin (Figure 3B).
Microarray data released recently by the Immgen consortium
(https://www.immgen.org) show that mast cells from the skin,
peritoneal cavity, trachea and esophagus express high level of
the Karma gene (Supplementary Figure S3), confirming our
observation. To the best of our knowledge, this is the first report
of a gene that is selectively shared by both cDC1 and mast
cells. The KarmaCre mice will therefore be of special interest
to researchers aiming at genetically manipulating mast cells in
tissues. In all tissues and in all mouse models examined, no
tdRFP expression was detected in the CD45-negative cells present
in cell suspensions (Figure 2). Although, we did not examine
tdRFP expression in other non-hematopoietic cells, it is unlikely
that some of these cell types would be targeted in Xcr1Cre or
KarmaCre mice considering that the Xcr1 and Gp141b genes were
not expressed outside of the hematopoietic system in all of the
transcriptomic databases we queried.
To inactivate specifically a candidate gene in cDC1, both
alleles of this candidate gene should be excised. This requires a
breeding strategy in which one Cre allele and one floxed allele
of the gene to be inactivated are brought by the same germ
cells, where unexpected recombination could occur. We have
tested the frequency of germline recombination for both the
Xcr1Cre and KarmaCre models. Only the Xcr1Cre model showed
adventitious Cre activity in germ cells resulting in progeny with
recombined Rosa26tdRFP locus in all their cells. Interestingly,
this was paternal inherited in this specific experimental setting.
However, this may depend on the loxP-flanked construct,
as we had events of germline recombination transmitted by
females for other floxed genes than the Rosa26tdRFP reporter.
Therefore, to reach specific recombination in cDC1 using
the Xcr1Cre model, the Cre allele and the loxP-flanked allele
should be inherited from different parents. We recommend
breeding one parent homozygous for both the Cre allele and
a null allele of the target gene, to another parent homozygous
for the floxed allele of the target gene. Each investigator
using the Xcr1Cre model should always test their progeny
for unexpected off-target recombination. A recent publication
strongly suggested to include, in each experimental procedure
of publication using Cre mouse models, detailed procedures
about the breeding strategies used and the method the
investigators applied to detect any unexpected and unspecific
recombination (56).
Our genetic tracing of cDC1 in vivo in the spleen (Figure 4),
or in vitro in FLT3-L-differentiated BM-DC cultures (Figure 5A)
revealed heterogeneity in the cDC1 population. The differential
expression of Xcr1 and Karma genes within the cDC1 population
qualifies Xcr1Cre and KarmaCre mouse models as powerful tools
to describe further these cDC1 subsets in vivo. In vitro, BM-
DCs derived from KarmaCre mice did not show any sign of
Cre activity (Figure 5A), confirming that the Karma gene is not
transcriptionally active in these cells as directly assessed through
their gene expression profiling (Figure 5B), akin to Cd8a or Ly75
(Dec205) (43). We show here that expression of the Karma gene
on cDC1 requires accessory signals, which can be provided upon
in vivo transfer, or in vitro by Notch signaling likewise to what
has been recently reported for Cd8a and Ly75 (43). Of note, in
FLT3-L in vitro BM-DC culture, detection in eq-cDC1 of the
activity of the Cre recombinase as readout by tdRFP expression
seemed to be delayed over time as compared to cell surface
acquisition of XCR1 (Figure 5), although the Cre and Xcr1 genes
were expressed under the same promoter from one bi-cistronic
mRNA. This might be explained by a delayed translation of the
Cre gene as compared to Xcr1, or because efficient recombination
of DNA by the Cre requires time. This latter case might especially
apply to the Rosa26tdRFP reporter mouse line used in this study,
because it was engineered as requiring two consecutive rounds of
Cre-excision to generate detectable tdRFP signal, in order to limit
any leaky transcription of the fluorescent reporter gene across the
stopper at steady state (35). This contrasts to most reporter lines
which require only one sequence of recombination to emit signal
(57, 58) and must therefore require lower and/or less sustained
Cre activity to allow recombination. Breeding the Xcr1Cre model
with a Cre-reporter mouse which is easily recombined (57) might
allow a better synchronization of XCR1 surface expression with
Cre activity.
Our results advanced our understanding of the differentiation
trajectory of cDC1, and validated the Xcr1Cre mouse model as a
robust tool to inactivate genes selectively in cDC1 either in vivo
or in vitro using BM-derived DC cultures. Future use of these
mutant mouse models will undoubtedly boost the advancing of
our understanding of the biology of cDC1.
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